Jubilant Pharmova Limited (JUBLPHARMA.BO)
INR 881.1
(-0.37%)
INR 881.1
(-0.37%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 8 Billion INR | 10.55% |
| 2022 | 7.57 Billion INR | -29.37% |
| 2021 | 11.67 Billion INR | -24.16% |
| 2020 | 13.92 Billion INR | -10.33% |
| 2019 | 15.52 Billion INR | -4.42% |
| 2018 | 14.93 Billion INR | 15.63% |
| 2017 | 14.66 Billion INR | 14.87% |
| 2016 | 13.65 Billion INR | 8.36% |
| 2015 | 12.39 Billion INR | 80.71% |
| 2014 | 6.95 Billion INR | -32.34% |
| 2013 | 10.29 Billion INR | -5.32% |
| 2012 | 8.36 Billion INR | 17.56% |
| 2011 | 5.6 Billion INR | 52.14% |
| 2010 | 5.95 Billion INR | -26.44% |
| 2009 | 8.09 Billion INR | 42.83% |
| 2008 | 5.66 Billion INR | -2.53% |
| 2007 | 5.81 Billion INR | 44.71% |
| 2006 | 4.01 Billion INR | 74.75% |
| 2005 | 2.29 Billion INR | 1.92% |
| 2004 | 2.25 Billion INR | 38.91% |
| 2003 | 1.62 Billion INR | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | 2.96 Billion INR | -55.13% |
| 2024 Q1 | 1.56 Billion INR | 465.78% |
| 2023 FY | - INR | 10.55% |
| 2023 Q4 | 2.71 Billion INR | 1.69% |
| 2023 Q2 | 2.6 Billion INR | 47.45% |
| 2023 Q1 | 1.76 Billion INR | -22.58% |
| 2023 Q3 | 2.66 Billion INR | 2.38% |
| 2022 Q3 | 1.53 Billion INR | -32.91% |
| 2022 Q4 | 2.28 Billion INR | 48.58% |
| 2022 FY | - INR | -29.37% |
| 2022 Q1 | 2.03 Billion INR | -14.63% |
| 2022 Q2 | 2.29 Billion INR | 12.52% |
| 2021 Q1 | 3.69 Billion INR | -5.04% |
| 2021 FY | - INR | -24.16% |
| 2021 Q2 | 3.42 Billion INR | -7.21% |
| 2021 Q3 | 2 Billion INR | -41.56% |
| 2021 Q4 | 2.38 Billion INR | 19.13% |
| 2020 Q2 | 3.53 Billion INR | 92.79% |
| 2020 Q1 | 1.83 Billion INR | -66.33% |
| 2020 Q3 | 4.93 Billion INR | 39.64% |
| 2020 Q4 | 3.88 Billion INR | -21.18% |
| 2020 FY | - INR | -10.33% |
| 2019 Q4 | 5.44 Billion INR | 31.54% |
| 2019 Q2 | 4.8 Billion INR | 8.19% |
| 2019 Q1 | 4.44 Billion INR | 26.39% |
| 2019 Q3 | 4.13 Billion INR | -13.95% |
| 2019 FY | - INR | -4.42% |
| 2018 Q4 | 3.51 Billion INR | -32.69% |
| 2018 Q3 | 5.22 Billion INR | 15.04% |
| 2018 Q2 | 4.54 Billion INR | 1.55% |
| 2018 FY | - INR | 15.63% |
| 2018 Q1 | 4.47 Billion INR | -7.01% |
| 2017 Q4 | 4.8 Billion INR | 14.46% |
| 2017 Q3 | 4.2 Billion INR | 34.14% |
| 2017 Q2 | 3.13 Billion INR | -9.08% |
| 2017 FY | - INR | 14.87% |
| 2017 Q1 | 3.44 Billion INR | 9.16% |
| 2016 Q2 | 3.45 Billion INR | -7.3% |
| 2016 Q1 | 3.72 Billion INR | 26.18% |
| 2016 FY | - INR | 8.36% |
| 2016 Q3 | 3.36 Billion INR | -2.41% |
| 2016 Q4 | 3.15 Billion INR | -6.36% |
| 2015 FY | - INR | 80.71% |
| 2015 Q4 | 2.95 Billion INR | -4.37% |
| 2015 Q3 | 3.08 Billion INR | -5.79% |
| 2015 Q2 | 3.27 Billion INR | -0.38% |
| 2015 Q1 | 3.28 Billion INR | 61.28% |
| 2014 Q4 | 2.03 Billion INR | 6.56% |
| 2014 FY | - INR | -32.34% |
| 2014 Q1 | 1.49 Billion INR | -36.65% |
| 2014 Q2 | 1.37 Billion INR | -8.19% |
| 2014 Q3 | 1.91 Billion INR | 39.27% |
| 2013 Q4 | 2.36 Billion INR | -7.48% |
| 2013 FY | - INR | -5.32% |
| 2013 Q2 | 2.76 Billion INR | 13.36% |
| 2013 Q1 | 2.43 Billion INR | -2.43% |
| 2013 Q3 | 2.55 Billion INR | -7.66% |
| 2012 Q1 | -8.38 Billion INR | -423.43% |
| 2012 Q3 | 2.77 Billion INR | -0.52% |
| 2012 FY | - INR | 17.56% |
| 2012 Q2 | 2.78 Billion INR | 133.24% |
| 2012 Q4 | 2.5 Billion INR | -9.87% |
| 2011 Q4 | 2.59 Billion INR | 22.24% |
| 2011 Q3 | 2.12 Billion INR | 0.0% |
| 2011 FY | - INR | 52.14% |
| 2010 FY | - INR | -26.44% |
| 2009 FY | - INR | 42.83% |
| 2008 FY | - INR | -2.53% |
| 2007 FY | - INR | 44.71% |
| 2006 FY | - INR | 74.75% |
| 2005 FY | - INR | 1.92% |
| 2004 FY | - INR | 38.91% |
| 2003 FY | - INR | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 9.61 Billion INR | 16.749% |
| Aurobindo Pharma Limited | 61.78 Billion INR | 87.043% |
| Glenmark Life Sciences Limited | 6.86 Billion INR | -16.657% |
| Granules India Limited | 8.6 Billion INR | 6.948% |
| Indoco Remedies Limited | 2.64 Billion INR | -202.449% |
| Achyut Healthcare Limited | 524 Thousand INR | -1527762.595% |
| Ajanta Pharma Limited | 12.56 Billion INR | 36.285% |
| Alkem Laboratories Limited | 24.19 Billion INR | 66.911% |
| Alpa Laboratories Limited | 86.12 Million INR | -9195.575% |
| Brooks Laboratories Limited | 41.72 Million INR | -19086.158% |
| AstraZeneca Pharma India Limited | 2.35 Billion INR | -239.698% |
| Bajaj HealthCare Limited | 444.51 Million INR | -1701.06% |
| Bliss GVS Pharma Limited | 1.47 Billion INR | -441.301% |
| Dr. Reddy's Laboratories Limited | 88.27 Billion INR | 90.931% |
| Eris Lifesciences Limited | 6.98 Billion INR | -14.593% |
| FDC Limited | 4.4 Billion INR | -81.885% |
| Glenmark Pharmaceuticals Limited | 11.34 Billion INR | 29.423% |
| Gufic Biosciences Limited | 1.48 Billion INR | -440.768% |
| Ind-Swift Laboratories Limited | 6.86 Billion INR | -16.678% |
| Ipca Laboratories Limited | 13.29 Billion INR | 39.802% |
| Jagsonpal Pharmaceuticals Limited | 323.46 Million INR | -2375.113% |
| Krebs Biochemicals & Industries Limited | -82.72 Million INR | 9777.614% |
| Lasa Supergenerics Limited | -65.08 Million INR | 12401.782% |
| Laurus Labs Limited | 8 Billion INR | 0.0% |
| Lupin Limited | 36.96 Billion INR | 78.344% |
| Mankind Pharma Limited | 28.09 Billion INR | 71.503% |
| Medicamen Biotech Limited | 245.66 Million INR | -3158.976% |
| Medico Remedies Limited | 150.37 Million INR | -5223.917% |
| Megasoft Limited | 284.73 Million INR | -2711.777% |
| NATCO Pharma Limited | 18.79 Billion INR | 57.404% |
| Piramal Pharma Limited | 13.05 Billion INR | 38.677% |
| RPG Life Sciences Limited | 1.28 Billion INR | -524.737% |
| Sigachi Industries Limited | 883.39 Million INR | -806.273% |
| Sun Pharmaceutical Industries Limited | 138.36 Billion INR | 94.214% |
| Suven Pharmaceuticals Limited | 4.67 Billion INR | -71.171% |
| Syncom Formulations (India) Limited | 430.27 Million INR | -1760.666% |
| Unichem Laboratories Limited | 742.35 Million INR | -978.458% |
| Wanbury Limited | 985.49 Million INR | -712.388% |
| Windlas Biotech Limited | 781.72 Million INR | -924.152% |
| ZIM Laboratories Limited | 462.09 Million INR | -1632.537% |
| Zydus Lifesciences Limited | 56.22 Billion INR | 85.76% |
| Sun Pharma Advanced Research Company Limited | -3.73 Billion INR | 314.565% |
| Divi's Laboratories Limited | 25.43 Billion INR | 68.517% |
| Hester Biosciences Limited | 539.47 Million INR | -1384.049% |
| Procter & Gamble Health Limited | 3.01 Billion INR | -165.592% |
| Amrutanjan Health Care Limited | 682.53 Million INR | -1072.975% |
| Bal Pharma Limited | 345.59 Million INR | -2216.605% |
| Strides Pharma Science Limited | 3.76 Billion INR | -112.661% |
| Venus Remedies Limited | 711.8 Million INR | -1024.753% |
| Aarti Pharmalabs Limited | 3.9 Billion INR | -104.787% |
| Nectar Lifesciences Limited | 1.56 Billion INR | -411.961% |
| Shilpa Medicare Limited | 2.58 Billion INR | -209.353% |
| Aarti Drugs Limited | 3.24 Billion INR | -146.442% |
| IOL Chemicals and Pharmaceuticals Limited | 2.6 Billion INR | -207.143% |
| Suven Life Sciences Limited | -992.78 Million INR | 906.422% |
| Ind-Swift Limited | 1.06 Billion INR | -651.691% |
| Valiant Laboratories Limited | 12.73 Million INR | -62746.377% |
| J. B. Chemicals & Pharmaceuticals Limited | 9.33 Billion INR | 14.235% |
| Solara Active Pharma Sciences Limited | -2.82 Billion INR | 383.71% |
| Themis Medicare Limited | 562.6 Million INR | -1323.018% |
| Hikal Limited | 2.69 Billion INR | -197.374% |
| Torrent Pharmaceuticals Limited | 35 Billion INR | 77.132% |
| Sequent Scientific Limited | 549.8 Million INR | -1356.166% |
| Novartis India Limited | 1.26 Billion INR | -530.741% |
| Wockhardt Limited | 1.08 Billion INR | -641.296% |
| Biofil Chemicals and Pharmaceuticals Limited | 13.06 Million INR | -61192.298% |
| Neuland Laboratories Limited | 4.74 Billion INR | -68.612% |
| Morepen Laboratories Limited | 1.72 Billion INR | -363.859% |
| Kilitch Drugs (India) Limited | 287.42 Million INR | -2685.422% |
| Mangalam Drugs & Organics Limited | 174.94 Million INR | -4476.269% |